[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,266,005
  • Shares Outstanding, K 192,402
  • Annual Sales, $ 42,730 K
  • Annual Income, $ -204,380 K
  • EBIT $ -197 M
  • EBITDA $ -188 M
  • 60-Month Beta -1.32
  • Price/Sales 29.13
  • Price/Cash Flow N/A
  • Price/Book 2.43

Options Overview Details

View History
  • Implied Volatility 82.82% (-32.48%)
  • Historical Volatility 48.01%
  • IV Percentile 23%
  • IV Rank 15.08%
  • IV High 199.53% on 11/05/25
  • IV Low 62.09% on 08/21/25
  • Expected Move (DTE 19) 1.06 (16.15%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 427
  • Volume Avg (30-Day) 1,845
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 39,547
  • Open Int (30-Day) 40,178
  • Expected Range 5.52 to 7.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.30
  • Low Estimate $-0.32
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.02 +9.30%
on 05/21/26
7.61 -13.59%
on 05/05/26
-0.47 (-6.67%)
since 04/29/26
3-Month
5.02 +31.08%
on 03/26/26
14.32 -54.05%
on 03/11/26
-7.35 (-52.76%)
since 02/27/26
52-Week
5.02 +31.08%
on 03/26/26
21.73 -69.72%
on 12/09/25
+0.53 (+8.76%)
since 05/28/25

Most Recent Stories

More News
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

WVE : 6.58 (+1.70%)
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly...

WVE : 6.58 (+1.70%)
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.58 (+1.70%)
Wave Life Sciences: Q1 Earnings Snapshot

Wave Life Sciences: Q1 Earnings Snapshot

WVE : 6.58 (+1.70%)
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the  Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the...

WVE : 6.58 (+1.70%)
Can Wave Life Sciences Convince Investors Its Obesity Data Justifies the Valuation?

Barchart Research What to Expect from WVE Earnings WVE Generated April 27, 2026 Current Price $6.94 EPS Estimate $$-0.34 Consensus Rating Strong Buy Average Move 4.91% Can Wave Life Sciences Convince Investors...

WVE : 6.58 (+1.70%)
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.58 (+1.70%)
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of...

WVE : 6.58 (+1.70%)
Wave Life Sciences Announces Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.58 (+1.70%)
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends loading up on WVE shares today.

WVE : 6.58 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 6.89
2nd Resistance Point 6.77
1st Resistance Point 6.67
Last Price 6.58
1st Support Level 6.46
2nd Support Level 6.34
3rd Support Level 6.24

See More

52-Week High 21.73
Fibonacci 61.8% 15.35
Fibonacci 50% 13.38
Fibonacci 38.2% 11.40
Last Price 6.58
52-Week Low 5.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.